Epitomee Medical
Caesarea, Israel· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A platform for pH‑triggered, biodegradable oral capsules that provide targeted GI therapy for chronic disease.
ObesityMetabolic DisordersGastroenterology
Technology Platform
Self‑expanding hydrogel scaffold folded into a swallowable capsule that deploys at pH‑specific GI locations, providing transient, biodegradable therapeutic activity.
Opportunities
Large, unmet need for oral delivery of biologics and weight‑management therapies; potential licensing deals with pharma to repurpose pipeline assets for the GI platform.
Risk Factors
Regulatory approval for novel ingestible devices; clinical validation of efficacy and safety; competition from established oral drug‑delivery technologies.
Competitive Landscape
Competes with other GI‑targeted delivery systems (e.g., Medtronic’s GI pumps, Intestine‑specific capsules) but differentiates through a fully biodegradable, pH‑triggered hydrogel scaffold that can be customized for multiple indications.